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Background. The use of cannabis with higher Δ9-tetrahydrocannabinol content has been associated with greater risk,
and earlier onset, of psychosis. However, the effect of cannabis potency on brain morphology has never been explored.
Here, we investigated whether cannabis potency and pattern of use are associated with changes in corpus callosum (CC)
microstructural organization, in patients with ﬁrst-episode psychosis (FEP) and individuals without psychosis, cannabis
users and non-users.
Method. The CC of 56 FEP (37 cannabis users) and 43 individuals without psychosis (22 cannabis users) was virtually
dissected and segmented using diffusion tensor imaging tractography. The diffusion index of fractional anisotropy, mean
diffusivity (MD), axial diffusivity (AD) and radial diffusivity was calculated for each segment.
Results. Across the whole sample, users of high-potency cannabis had higher total CC MD and higher total CC AD than
both low-potency users and those who never used (p = 0.005 and p = 0.004, respectively). Daily users also had higher total
CC MD and higher total CC AD than both occasional users and those who never used (p = 0.001 and p < 0.001, respect-
ively). However, there was no effect of group (patient/individuals without psychosis) or group x potency interaction for
either potency or frequency of use. The within-group analysis showed in fact that the effects of potency and frequency
were similar in FEP users and in users without psychosis.
Conclusions. Frequent use of high-potency cannabis is associated with disturbed callosal microstructural organization
in individuals with and without psychosis. Since high-potency preparations are now replacing traditional herbal drugs in
many European countries, raising awareness about the risks of high-potency cannabis is crucial.
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Introduction
Cannabis use has been associated with an increased risk
of subsequent psychosis (Henquet et al. 2008; Casadio
et al. 2011). Our group has previously shown that this
risk is greater, and onset occurs earlier, in those indivi-
duals who use more frequently and those who use can-
nabis with higher Δ9-tetrahydrocannabinol (THC)
content (high-potency types such as ‘skunk’) (Di Forti
et al. 2009, 2014). Exploring the role of potency in
increasing the risk of psychosis has become particularly
important since, over the last decade, modern ‘high-
potency’ products (sinsemilla or ‘skunk’) in ‘street can-
nabis’ have been found to have higher THC (16–22%)
and lower cannabidiol (CBD) (<0.1%) content (Potter
et al. 2008). Interestingly, the THC component of canna-
bis has been proposed to have a neurotoxic effect on the
brain (Gilman et al. 2014), while the CBD component
has been proposed to be actually neuroprotective
(Pertwee, 2008). While the long-term use of cannabis
has been associated with alterations in both brain func-
tion and morphology (Lorenzetti et al. 2010; Schacht
et al. 2012; Battistella et al. 2014), the effect of potency
on the brain has never been explored.
THC acts on cannabinoid-1 (CB1) receptors, which,
among other effects, modulate a variety of glial cell
functions, including oligodendrocytes, and may induce
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microstructural changes in white matter (WM) (Walter
et al. 2003). Indeed, oligodendrocyte survival is affected
by cannabis exposure during development, with conse-
quent alteration of normal WM development in animals
(Molina-Holgado et al. 2002). The largest WM tract, the
corpus callosum (CC), is of particular interest in
humans, since it is very rich in cannabinoid receptors
during neurodevelopment. As the CC has a fundamen-
tal role in inter-hemispheric connectivity, it is not sur-
prising that this structure has been widely implicated
in both psychosis and cannabis-associated behaviours
(Arnone et al. 2006; Walterfang et al. 2008).
Alterations in the microstructural organization of the
CC and other WM structures have been reported in
patients with psychosis in vivo using diffusion tensor
imaging (DTI) (Brambilla et al. 2005; Kanaan et al.
2005; Shergill et al. 2007; Cheung et al. 2008;
Kyriakopoulos et al. 2008). While some studies have
suggested that alterations are uniformly distributed
along the CC, others have suggested that certain seg-
ments may be particularly affected. For example, the
splenium and the genu seem to be the most affected
areas and those that most contribute to the lower CC
fractional anisotropy (FA – a measure of the degree
of directionality and coherence of WM ﬁbres) observed
in individuals with schizophrenia (Buchsbaum et al.
2006; Friedman et al. 2008; Kubicki et al. 2008;
Gasparotti et al. 2009). However, only three studies
have speciﬁcally evaluated diffusion microstructural
properties of WM in patients with psychosis who
were also cannabis users, with inconsistent ﬁndings
(Peters et al. 2009; Dekker et al. 2010; James et al.
2011). Two studies found that early cannabis use in
patients with schizophrenia was associated with
increased FA in the splenium of the CC (Dekker et al.
2010), and of other tracts such as the uncinate fascic-
ulus, internal capsule and frontal WM (Peters et al.
2009). In contrast, the third study found that early can-
nabis use was associated with lower FA in the brain
stem, internal capsule, corona radiata, and superior
and inferior longitudinal fasciculi (James et al. 2011).
These inconsistencies could be due to the use of
small samples, the presence of co-morbidities, and,
above all, differences in the assessment of cannabis
consumption. In fact, no study to date has examined
the relationship between potency of cannabis used
and CC microstructure.
Interestingly, changes in CC integrity have often
been observed in individuals without psychosis but
with a history of heavy and long-term cannabis use.
These include increase in mean diffusivity (MD – a
measure of the average mobility of water molecules,
affected by cellular density, extracellular space volume
and the overall water content, impairment in axonal
connectivity, and reductions in global efﬁciency),
indicating a less efﬁcient and/or slower information
transfer across the whole brain (Gruber et al. 2005;
Arnone et al. 2008; Zalesky et al. 2012).
Here, we have investigated for the ﬁrst time the ef-
fect of cannabis potency, as well as of frequency and
age of ﬁrst use, on the microstructural organization
of the CC using DTI, in a sample of cannabis users
and non-users, with and without psychosis. We
hypothesized that CC microstructural organization
would be particularly affected in individuals who use
higher-potency cannabis, independently of frequency
and age of ﬁrst use. We additionally explored whether
this effect would be stronger in those individuals with
concomitant psychosis, and also investigated which
speciﬁc segment of the CC, if any, would be altered
in relation to cannabis potency.
Method
Sample
A total of 56 patients with ﬁrst-episode psychosis (FEP)
were recruited from South East London (UK). Also, 43
individuals without psychosis were recruited from the
same geographical area; they were administered the
Psychosis Screening Questionnaire (Bebbington et al.
1995), and excluded if they reported any psychotic
symptom or a history of psychotic illnesses.
Exclusion criteria for all subjects included: history of
head trauma or injury with loss of consciousness
longer than 1 h; current or past organic psychosis;
learning disabilities or lack of English ﬂuency (for
details, see Di Forti et al. 2009, 2014). Ethical approval
was obtained from the local ethics committee. After a
complete description of the study, written informed
consent was obtained. All patients underwent clinical
and magnetic resonance imaging (MRI) assessments,
as soon as possible after their ﬁrst contact with ser-
vices. Individuals without psychosis underwent the
same neuroimaging assessment. At the time of the
MRI, 48 patients were taking atypical antipsychotics,
ﬁve were taking typical antipsychotics and three
were antipsychotic naive.
Clinical assessment
International Classiﬁcation of Diseases (ICD)-10 diag-
noses were formulated by qualiﬁed psychiatrists
using the Operational Criteria Checklist for Psychotic
Illness (OPCRIT+) (McGufﬁn et al. 1991), which
shows good inter-rater reliability (κ = 0.9). The sample
included 14 patients with a diagnosis of schizophrenia,
12 acute psychotic disorders, eight schizo-affective dis-
order, ﬁve unspeciﬁed non-organic psychosis, 10 bipo-
lar affective disorder and seven severe depressive
episode with psychotic symptoms. Severity of
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psychotic symptoms was assessed with the Positive
and Negative Syndrome Scale (PANSS) (Kay et al.
1987). Duration of untreated psychosis was quantiﬁed
as the interval between ﬁrst onset of psychotic symp-
toms and ﬁrst contact with psychiatric services.
Psychosis onset was deﬁned using the Nottingham
Onset Schedule (Singh et al. 2005).
Antipsychotic doses were converted to chlorpro-
mazine equivalents (Woods, 2003), and length of expos-
ure calculated in number of days. Finally, handedness
was evaluated with the Annett Hand Preference
Questionnaire (Annett, 1970).
Assessment of cannabis use
A detailed history of illicit drug use (cannabis, stimu-
lants and any other recreational drug) was taken
using the Cannabis Experience Questionnaire modiﬁed
version (Di Forti et al. 2009). This allows a detailed as-
sessment of lifetime patterns of cannabis use, includ-
ing: frequency and duration of use, the speciﬁc type
of cannabis used and age at ﬁrst use. The measures
of exposure to cannabis use included in the analyses
were: (a) lifetime history of cannabis use (had the
subject ever used cannabis at any point in the lifetime:
no = 0; yes = 1); (b) lifetime frequency of cannabis use
[the frequency that characterized the subject’s most
consistent pattern of use: none = 0; at weekends or
less frequently (occasional)=1; every day (daily)=2];
(c) type of cannabis used [the potency of cannabis
used that characterized the subject’s most consistent
pattern of use: no = 1; low-potency (hash-like)=2; high-
potency (skunk-like)=3]; (d) age at ﬁrst use (the age
when the subject started to use cannabis regularly:
prior to age 15 years = 0; above age 15 years = 1).
Evaluating frequency of use with this approach esti-
mates the pattern that represents most of the subject’s
use during his/her period of cannabis use, and distin-
guishes those individuals who have been mostly regu-
lar users from those who have been more occasional
users. Pattern of cannabis use in patients and indivi-
duals without psychosis is detailed in Table 1.
DTI
Image acquisition
Data were acquired on a 3.0-Tesla, using a GE
Signa-HDx system running software release 14M5,
with actively shielded magnetic ﬁeld gradients (max-
imum amplitude 40 mT/m). A body coil was used for
radiofrequency transmission, and an eight-channel
head coil for signal reception, allowing a parallel im-
aging (ASSET) speed up factor of two. Each volume
was acquired using a multi-slice peripherally gated
doubly refocused spin echo planar imaging (EPI)
sequence, optimized for precise measurement of the
diffusion-tensor in parenchyma, from 60 contiguous
near-axial slice locations with isotropic (2.4 × 2.4 ×
2.4 mm) voxels. Echo time was 104.5 ms and effective
repetition time varied between 12 and 20 R-R intervals.
Acquisition was gated to the cardiac cycle using a per-
ipheral gating device. Maximum diffusion weighting
was 1300 s/mm2, and at each slice location, four images
were acquired with no diffusion gradients applied, to-
gether with 32 diffusion-weighted images with gradi-
ent directions uniformly distributed in space. An
in-house automated analysis technique assessed the
quality of EPI data.
Image processing
The raw diffusion dataset was then submitted to a full
quality-control check, where all b = 0 values and
diffusion-weighted volumes were visually inspected
using the light-box function available inside fslview
for any image corruption, motion artifacts and signal
drop-out effects. Any dataset showing signiﬁcant
head movements (>1 cm) or more than two motion
artifacts in different volumes on the same slice were
removed from the study. Diffusion data were pro-
cessed using ExploreDTI (Leemans et al. 2009). Data
were ﬁrst pre-processed correcting for eddy current
distortions and head motion. For each subject the
b-matrix was then reoriented to provide a more accur-
ate estimate of tensor orientations. The diffusion tensor
was estimated using a non-linear least square approach
(Jones et al. 2002), with FA, MD, radial diffusivity (RD)
and axial diffusivity (AD) calculated from the diffusion
tensor. We report on RD and AD measures as they can
provide information on the nature of changes present
in WM tracts. For example, RD has been suggested
to be a marker of reduction in myelin content, repre-
senting an index of axonal demyelination, while AD
is indicative of axonal damage (Beaulieu et al. 2002).
Tractography analysis
Tractography was started in all brain voxels with FA >
0.2. Streamlines were propagated using Euler integra-
tion applying a b-spline interpolation of the diffusion
tensor ﬁeld (Basser et al. 1994), and the tractography al-
gorithm step size of 0.5 mm.WhenFAwas <0.2, orwhen
the angle between two consecutive tractography steps
was larger than 30 ×, tractography stopped. Finally,
FA, MD, RD and AD indices were measured along the
tract using TrackVis v0.4.3 software (Wang et al. 2007).
CC dissection
TrackVis (http://www.trackvis.org) was used for vir-
tual dissection of the CC. In order to dissect this
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Table 1. Demographic and clinical characteristics and patterns of cannabis use
First-episode psychosis
patients (n = 56)
Individuals without
psychosis (n = 43) Test statisticsa
Mean age, years (S.D.) 28.8 (8) 27.4 (10) df = 93, t = 0.85, N.S.
Gender, n χ2 = 2.66, N.S.
Male 31 22
Female 25 21
Mean duration of education, years (S.D.) 13.4 (3.5) 14.7 (3.0) df = 93, t =−1.86, p = 0.06
Ethnicity, n (%)
White Caucasian 19 (37) 18 (50) χ2 = 2.87, N.S.
Black Caribbean 9 (17) 7 (20)
Black African 14 (27) 8 (22)
Other 10 (19) 3 (8)
Diagnosis by ICD-10, n – –
Schizophrenia 14
Acute psychotic disorder 12
Schizo-affective disorder 8
Unspeciﬁed non-organic psychosis 5
Bipolar affective disorder 10
Depressive episode with psychotic symptoms 7
Mean total antipsychotic dose, CPZ equivalents (S.D.) 7830.7 (8838.0) – –
Mean DUP, days (S.D.) 116 (182) – –
Mean PANSS score (S.D.)
Total 52.7 (13.5) – –
Positive 12.2 (15.3)
Negative 13.1 (15.6)
General 27.6 (17.6)
Ever used cannabis, n (%) 37 (70) 22 (52) df = 1, χ2 = 4.0, p = 0.04
Mean duration of cannabis use, years (S.D.)b 7.6 (9) 7.2 (5) df = 43, t = 1.0, N.S.
Type of cannabis used, n (%)c
No cannabis use 16 (32) 22 (55) df = 2, χ2 = 5.6, p = 0.06
Low potency (hash-like) 11 (22) 6 (15)
High potency (skunk-like) 23 (46) 12 (30)
Age at ﬁrst use, n (%)
<15 years 12 (32.4) 6 (27.3) df = 1, χ2 = 0.2, N.S.
>15 years 25 (67.6) 16 (72.7)
Frequency of use, n (%)d
Occasional 11 (30) 11 (50) df = 2, χ2 = 5.3, p = 0.07
Daily 25 (70) 11 (50)
Other drugs, n (%)e 22 (64.7) 12 (35.3) df = 2, χ2 = 5.9, p = 0.05
Mean TIV, ml (S.D.) 1716.5 (201.8) 1726.7 (175.8) df = 90, t =−0.52, N.S.
Mean WMV, ml (S.D.) 449.8 (51.0) 458.8 (55.8) df = 90, t =−0.81, N.S.
Mean GMV, ml (S.D) 751 (100.7) 775.5 (83.1) df = 90, t =−1.26, N.S.
Mean CSF, ml (S.D.) 513.1 (121.2) 486.8 (109.1) df = 90, t = 1.1, N.S.
S.D., Standard deviation; df, degrees of freedom; N.S., non-signiﬁcant; ICD, International Classiﬁcation of Diseases; CPZ,
chlorpromazine; DUP, duration of untreated psychosis; PANSS, Positive and Negative Syndrome Scale; TIV, total intracranial
volume; WMV, white matter volume; GMV, grey matter volume; CSF, cerebrospinal ﬂuid.
a Only p’s < 0.1 are reported.
b Lack of details for one patient and one control.
c Lack of details for six patients and three controls.
d Lack of details for one patient.
e Lack of details for 16 patients and 11 controls.
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tract, a single region of interest (ROI) was used as pre-
viously described (Catani et al. 2002; Catani & Thiebaut
de Schotten, 2008). To include the entirety of the CC
and avoid false-negative ﬁbres, the single ROI was
drawn large-sized around the CC on a mid-sagittal
slice, following the anatomy of the different segments
of this tract and according to a priori anatomical knowl-
edge (Yasmin et al. 2009). All false-positive compo-
nents were removed using one or more NOT-ROI,
which is an ROI used for the exclusion of ﬁbres consid-
ered not to be part of the CC.
CC segmentation
The subsections of the CC were deﬁned according to
the geometrical instructions given by Witelson (1989).
The maximal length of the CC was taken as the line
joining the most anterior and posterior point of the cal-
losum. Perpendiculars to this axis were drawn at
speciﬁc arithmetic divisions resulting in callosal seg-
ments, which are shown in Fig. 1b. The length of CC
could then be divided into the fractions described by
Witelson (1989), using a new ROI for each subsection.
These include: genu, rostral body, anterior mid-body,
posterior mid-body, isthmus and splenium (Fig. 1).
The ROI for each subsection spans the proportion of
the total CC length assigned to it by the Witelson sub-
divisions (for example, the splenium ROI was one-ﬁfth
of the anterior–posterior length of the ROI), and per-
pendicular height (inferior to superior) at least equal
to the corresponding part of the CC ROI, forming a
rectangle.
Data analysis
Sociodemographic characteristics were examined with
t tests or χ2 as appropriate. We ﬁrst examined differ-
ences in CC microstructure between FEP patients and
individuals without psychosis using multivariate ana-
lyses of covariance (MANCOVAs), with FA, MD, RD
and AD values of the whole CC as dependent vari-
ables, group as ﬁxed factor (patients v. individuals
Fig. 1. Corpus callosum tract: whole (a) and segmented (b). Regions of interest as deﬁned according to Witelson (1989)
subdivisions. RB, Rostral body; AMB, anterior mid-body; PMB, posterior mid-body; Ism, isthmus. For a colour ﬁgure, see the
online version.
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without psychosis), and age and gender as covariates
of no interest. To examine the effect of cannabis on
CC microstructure (for total CC and its subregions)
across the whole sample, the same analyses were per-
formed with potency of cannabis (no use, low potency,
high potency), frequency of use (never, occasional,
daily), cumulative effect of potency/frequency (daily/
high-potency users, daily/low-potency users, never
used/used weekly) and age at ﬁrst use (<or >15
years) separately entered as ﬁxed factors. Finally,
these analyses where repeated on an exploratory
basis separately for patients with psychosis and indivi-
duals without psychosis.
Results
Patients and individuals without psychosis were simi-
lar in terms of age, gender and ethnicity, although
patients had, as expected, a lower level of education
than individuals without psychosis (t = 1.86, p = 0.06)
(Table 1). Patients were more likely to have ever
used cannabis than individuals without psychosis.
However, there was no signiﬁcant difference between
patients and individuals without psychosis for years
of cannabis use, age at ﬁrst use, type of cannabis use,
frequency of use and potency of cannabis used.
There was also no signiﬁcant difference between
groups for alcohol use (χ2 = 0.12, p = 0.7) or alcohol in-
take in terms of units per week (χ2 = 4.6, p = 0.2).
Patterns of cannabis use did not signiﬁcantly differ
across diagnoses (χ2 = 24.8, p = 0.08 for frequency of
use; χ2 = 22.4, p = 0.1 for potency; χ2 = 7.1, p = 0.3 for
age at ﬁrst use; and χ2 = 20.2, p = 0.2 for the combined
effect of frequency and potency).
CC microstructural organization
Patients showed a signiﬁcantly lower total CC FA
(F1,93 = 4.1, p = 0.04) than individuals without psych-
osis. Patients also had higher, albeit non-signiﬁcantly,
total CC MD values than individuals without psych-
osis (F1,93 = 2.3, p = 0.09). Furthermore, patients had
higher total CC RD and AD values than individuals
without psychosis, although this difference was not
statistically signiﬁcant (F1,93 = 1.76, p > 0.05 and F1,93 =
1.78, p > 0.05, respectively).
CC microstructural organization and potency of
cannabis use
When we explored the effect of cannabis potency
across the whole group (patients and individuals with-
out psychosis), we observed a signiﬁcant effect on total
CC MD (F2,82 = 5.7, p = 0.005), with high-potency users
showing signiﬁcantly higher MD than both low-
potency users and those who never used, who in
contrast had similar MD values (Table 2). There was
no effect of group (patient/individuals without psy-
chosis) (F = 1.2, N.S.) or group x potency interaction
(F = 0.2, N.S.) on MD values. Likewise, none of the
covariates had a signiﬁcant effect (all p > 0.05). The
analyses on the CC subsections showed that, com-
pared with both low-potency users and those who
never used, the users of high-potency cannabis had
higher MD of the splenium (F2,80 = 4.5, p = 0.01) and
of the genu (F2,80 = 4.4, p = 0.02).
High-potency users also showed signiﬁcantly higher
AD (F2,82 = 6.05, p = 0.004), and higher RD (F2.82 = 3.4,
p = 0.04), than both low-potency users and those who
never used (Table 2). There was no effect of group
(patient/individuals without psychosis) (F = 0.1, N.S.)
or group x potency interaction (F = 1.3, N.S.) on AD
values. The exploratory analysis of the CC subsections
showed that, compared with both low-potency users
and those who never used, users of high-potency can-
nabis had signiﬁcantly higher AD, at trend level in the
genu (F2,82 = 2.7, p = 0.06) of the CC. Finally, there was
no effect of potency on FA values.
For completion, we investigated the effect of canna-
bis potency separately in patients and in individuals
without psychosis (Table 2). In patients, high-potency
users showed higher mean total CC MD and AD
than both low-potency users and those who never
used, albeit the difference was not statistically signiﬁ-
cant (F2,45 = 1.86, p = 0.16; and F2,45 = 1.85, p = 0.16,
respectively). Also, among individuals without psych-
osis high-potency users showed signiﬁcantly higher
total CC MD, higher CC AD, and at trend level CC
RD, than both low-potency users and those who
never used. Finally, there was no effect of potency
on FA values in both groups. Comparisons of
the CC subsections are presented in the online
Supplementary material.
CC microstructural organization and frequency of
cannabis use
Across the whole group, we found a signiﬁcant effect
of frequency of use on total CC MD (F2,87 = 7.5, p =
0.001), with daily users having signiﬁcantly higher
MD than both occasional users and those who never
used. There was no effect of group (F = 1.8, N.S.) or
group x frequency interaction (F = 0.2, N.S.) (Table 2).
Likewise, none of the covariates showed a signiﬁcant
effect on these MD differences (all p > 0.05). The ex-
ploratory analysis of the CC subsections showed that
the daily users, compared with both occasional users
and those who never used, had higher MD in the
splenium (F2.87 = 11.6, p < 0.001) and the genu (F2,87 =
4.9, p = 0.01).
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Table 2. Corpus callosum microstructural integrity and patterns of cannabis use (potency, frequency and age at ﬁrst use) across the sample as a whole, and in the two samples of patients with ﬁrst-episode
psychosis and individuals without psychosis
Potency of cannabis use Frequency of cannabis use Age at ﬁrst use
Corpus callosum
measure Never used
Low
potency
High
potency Statisticsa Never used
Occasional
users
Daily
users Statisticsa <15 years old >15 years old Statisticsa
Mean FA (S.D.):
Whole sample 0.576
(0.01)
0.574
(0.01)
0.573
(0.01)
F2,82 = 1.8, N.S. 0.576
(0.01)
0.573
(0.01)
0.572
(0.01)
F2,87 = 0.6, N.S. 0.573
(0.01)
0.574
(0.01)
F1,41 = 0.01, N.
S.
Patients with
psychosis
0.572
(0.01)
0.572
(0.01)
0.572
(0.02)
F2,45 = 0.39, N.S. 0.575
(0.01)
0.572
(0.01)
0.571
(0.01)
F2,48 = 0.9, N.S. 0.571
(0.01)
0.572
(0.02)
F1,23 = 0.1, N.S.
Individuals
without
psychosis
0.582
(0.01)
0.574
(0.01)
0.574
(0.01)
F2,35 = 2.4, N.S. 0.578
(0.01)
0.576
(0.01)
0.573
(0.01)
F2,37 = 0.5, N.S. 0.577
(0.01)
0.575
(0.01)
F1,18 = 0.4, N.S.
Mean MD, × 10−3 mm2/s (S.D.)
Whole sample 0.791
(0.02)
0.794
(0.02)
0.807
(0.02)
F2,82 = 5.7,
p = 0.005b
0.791
(0.01)
0.792
(0.02)
0.808
(0.01)
F2,87 = 7.5,
p = 0.001c
0.805
(0.02)
0.801
(0.02)
F1,41 = 0.5, N.S.
Patients with
psychosis
0.794
(0.02)
0.798
(0.01)
0.808
(0.02)
F2,45 = 1.86, N.S. 0.795
(0.02)
0.796
(0.01)
0.809
(0.02)
F2,48 = 2.87,
p = 0.06d
0.809
(0.02)
0.802
(0.01)
F1,23 = 0.38,
N.S.
Individuals
without
psychosis
0.788
(0.02)
0.789
(0.02)
0.810
(0.01)
F2,35 = 4.32,
p = 0.02e
0.786
(0.02)
0.790
(0.02)
0.807
(0.02)
F2,37 = 4.83,
p = 0.01f
0.811
(0.01)
0.791
(0.02)
F1,18 = 3.64,
p = 0.07d
Mean RD, × 10−3 mm2/s (S.D.)
Whole sample 0.491
(0.01)
0.492
(0.02)
0.502
(0.02)
F2,82 = 3.4,
p = 0.04d
0.488
(0.02)
0.492
(0.02)
0.502
(0.02)
F2,87 = 4.3,
p = 0.02d
0.499
(0.02)
0.497
(0.02)
F1,41 = 0.1, N.S.
Patients with
psychosis
0.494
(0.02)
0.496
(0.02)
0.503
(0.02)
F2,45 = 1.33, N.S. 0.495
(0.02)
0.492
(0.01)
0.504
(0.02)
F2,48 = 2.3 , N.S. 0.499
(0.02)
0.504
(0.02)
F1,23 = 0.2, N.S.
Individuals
without
psychosis
0.489
(0.01)
0.481
(0.01)
0.499
(0.01)
F2,35 = 2.88,
p = 0.07
0.483
(0.01)
0.490
(0.01)
0.498
(0.01)
F2,37 = 2.5, N.S. 0.500
(0.01)
0.487
(0.01)
F1,18 = 2.4, N.S.
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Table 2 (cont.)
Potency of cannabis use Frequency of cannabis use Age at ﬁrst use
Corpus callosum
measure Never used
Low
potency
High
potency Statisticsa Never used
Occasional
users
Daily
users Statisticsa <15 years old >15 years old Statisticsa
Mean AD, × 10−3 mm2/s (S.D.)
Whole sample 1.39
(0.02)
1.40
(0.03)
1.41
(0.03)
F2,82 = 6.05,
p = 0.004g
1.39
(0.03)
1.40
(0.03)
1.42
(0.03)
F2,87 = 8.9,
p < 0.001h
1.41
(0.03)
1.40
(0.03)
F1,41 = 0.8, N.S.
Patients with
psychosis
1.39
(0.03)
1.40
(0.02)
1.41
(0.02)
F2,45 = 1.85, N.S. 1.39
(0.02)
1.40
(0.02)
1.41
(0.03)
F2,48 = 2.1, N.S. 1.42
(0.03)
1.40
(0.02)
F1,23 = 0.5, N.S.
Individuals
without
psychosis
1.38
(0.03)
1.39
(0.04)
1.42
(0.03)
F2,35 = 4.2,
p = 0.02i
1.38
(0.03)
1.39
(0.02)
1.42
(0.03)
F2,37 = 5.7,
p = 0.007j
1.43
(0.04)
1.39
(0.03)
F1,18 = 2.8,
p = 0.4
FA, Fractional anisotropy; S.D., standard deviation; N.S., non-signiﬁcant; MD, mean diffusivity; RD, radial diffusivity; AD, axial diffusivity.
a Only p’s < 0.1 are reported. Post-hoc comparisons are given in notes b to j, all Bonferroni corrected.
b High-potency users had higher corpus callosum MD than those who never used (p = 0.004).
c Daily users had higher corpus callosum MD than those who never used (p = 0.002), and those who used weekly or less (p = 0.004).
d Did not survive Bonferroni correction.
e High-potency users had higher corpus callosum MD than those who never used (p = 0.02).
f Daily users had higher corpus callosum MD than those who never used (p = 0.02), and those who used weekly or less (p = 0.03).
g High-potency users had higher corpus callosum AD than those who never used (p = 0.002).
h Daily users had higher corpus callosum AD than those who never used (p = 0.001), and those who used weekly or less (p = 0.006).
i High-potency users had higher corpus callosum AD than those who never used (p = 0.02).
j Users had higher corpus callosum AD than those who never used (p = 0.008), and those who used weekly or less (p = 0.03).
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We observed no effect of frequency of use on FA
values. However, there was a signiﬁcant effect of fre-
quency on total CC AD (F2,87 = 8.9, p < 0.001) and on
total CC RD (F2,87 = 4,3, p = 0.02) values, with daily
users having a signiﬁcantly higher AD and RD values
than both occasional users and those who never used.
There was no effect of group (patient/individuals with-
out psychosis) (F = 0.7, N.S.; F = 2.3, N.S., for AD and RD,
respectively) or group x potency interaction (F = 2.0,
N.S.; F = 0.1, N.S., for AD and RD, respectively) on
these values. The analysis of the CC subsections
showed that, compared with both occasional users
and those who never used, the daily users had higher
AD in the genu (F2,87 = 3.93, p = 0.03) of the CC.
For completion, we investigated the effect of canna-
bis frequency separately in patients and individuals
without psychosis (Table 2). In patients, every-day
users showed higher mean total CC MD and total
CC AD than both occasional users and those who
never used, although the difference was at trend level
for MD (F2,48 = 2.87, p = 0.06) and not statistically sign-
iﬁcant for AD (F2,48 = 2.1, p = 0.1). Also, among indivi-
duals without psychosis, every-day users showed
signiﬁcantly higher total CC MD and total CC AD
than both occasional users and those who never
used. Finally, there was no effect of frequency in FA
and RD. Comparisons of the CC subsections are pre-
sented in the online Supplementary material.
CC microstructural organization and the cumulative
effect of potency and frequency of cannabis use
Since a considerable number of subjects who used
high-potency cannabis were also daily users, and
both high potency and daily frequency were signiﬁ-
cantly associated with altered CC integrity, we con-
ducted an additional MANCOVA using a cumulative
score for each individual, to capture the effect of
Table 3. Corpus callosum microstructural integrity: cumulative effect of frequency and potency of cannabis use across the sample as a whole,
and in the two samples of patients with ﬁrst-episode psychosis and individuals without psychosis
Corpus callosum measure
Cumulative effect of frequency and potency
Never used or
used weekly
Every day
low potency
Every day
high potency Statisticsa
Mean FA (S.D.)
Whole sample 0.574 (0.01) 0.574 (0.01) 0.573 (0.01) F2,82 = 0.7, N.S.
Patients with psychosis 0.573 (0.01) 0.572 (0.01) 0.570 (0.01) F2,45 = 0.7, N.S.
Individuals without psychosis 0.588 (0.01) 0.576 (0.02) 0.574 (0.01) F2,35 = 1.32, N.S.
Mean MD, × 10−3 mm2/s (S.D.)
Whole sample 0.792 (0.02) 0.798 (0.02) 0.810 (0.02) F2,82 = 7.3, p = 0.001
b
Patients with psychosis 0.794 (0.02) 0.807 (0.02) 0.809 (0.02) F2,45 = 2.8, p = 0.07
c
Individuals without psychosis 0.771 (0.01) 0.790 (0.01) 0.810 (0.01) F2,35 = 6.1, p = 0.005
d
Mean RD, × 10−3 mm2/s (S.D.)
Whole sample 0.491 (0.01) 0.495 (0.02) 0.502 (0.02) F2,82 = 3.7, p = 0.03
e
Patients with psychosis 0.494 (0.02) 0.504 (0.02) 0.504 (0.03) F2,45 = 1.9, N.S.
Individuals without psychosis 0.469 (0.01) 0.489 (0.01) 0.499 (0.01) F2,35 = 3.6, p = 0.04
f
Mean AD, × 10−3 mm2/s (S.D.)
Whole sample 1.39 (0.03) 1.40 (0.03) 1.42 (0.03) F2,82 = 8.8, p4 0.001
g
Patients with psychosis 1.39 (0.02) 1.41 (0.03) 1.42 (0.02) F2,45 = 2.8, p = 0.07
c
Individuals without psychosis 1.38 (0.03) 1.39 (0.04) 1.43 (0.03) F2,35 = 6.05, p = 0.006
h
FA, Fractional anisotropy; S.D., standard deviation; N.S., non-signiﬁcant; MD, mean diffusivity; RD, radial diffusivity; AD,
axial diffusivity.
a Only p’s < 0.1 are reported. Post-hoc comparisons are given in notes b to h, all Bonferroni corrected.
b Every day high-potency users had higher corpus callosum MD than those who never used or used weekly (p = 0.001), and
those who used every day low-potency cannabis (p = 0.09).
c Did not retain statistical signiﬁcance.
d Every-day high-potency users had higher corpus callosum MD than those who never used or used weekly (p = 0.013), and
those who used every day low-potency cannabis (p = 0.044).
e High-potency users had higher corpus callosum RD than those who never used or used weekly (p = 0.04).
f Did not retain statistical signiﬁcance.
g High-potency users had higher corpus callosum AD than those who never used or used weekly (p < 0.001).
h Every-day high-potency users had higher corpus callosum AD than those who never used or used weekly (p = 0.006).
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frequency and potency combined (Table 3). We com-
pared: (i) subjects who used high-potency cannabis
on a daily basis, v. those who (ii) used low-potency
cannabis on a daily basis, and v. those who (iii)
never used or only used weekly. This analysis showed
that the daily/high-potency users had a signiﬁcantly
higher total CC MD (F2,82 = 7.3, p = 0.001), CC AD
(F2,82 = 8.8, p < 0.001) and CC RD (F2,82 = 3.7, p = 0.03)
than those who never used/used weekly, while the
daily/low-potency users had CC MD values inter-
mediate between the two but were not signiﬁcantly
different from either. This suggests that the effect of
frequency is particularly marked when high-potency
compounds are used.
The exploratory analysis of the CC subsections
showed that the daily/high-potency users had a signiﬁ-
cantly higher MD than those who used low-potency
cannabis daily and those who never used/used weekly
in the splenium (F2,80 = 8.7, p < 0.001) and the genu
(F2,80 = 3.9, p = 0.03) of the CC; and higher AD in the
genu (F2,82 = 4.2, p = 0.02).
For completion, we investigated the combined effect
of cannabis frequency and potency separately in
patients and individuals without psychosis (Table 3).
In patients, daily/high-potency users showed higher
mean total CC MD and total CC AD than those who
used low-potency cannabis daily and those who
never used/used weekly, although the difference was
not statistically signiﬁcant. Also, among individuals
without psychosis daily/high-potency users had a sign-
iﬁcantly higher total CC MD, total CC AD and total
CC RD than both those who used low-potency canna-
bis daily and those who never used/used weekly.
Finally there was no effect of the combined effect of
cannabis frequency and potency in FA. Comparisons
of the CC subsections are presented in the online
Supplementary material.
CC microstructural organization and age at ﬁrst use
Finally, we evaluated the effect of age at ﬁrst use on
CC integrity across the whole group, and found no
signiﬁcant differences in any CC metrics between
early (<15 years) and late cannabis users (>15 years)
(F1,41 = 0.1, p = 0.5) (Table 2).
For completion, we investigated the effect of age at
ﬁrst use separately in patients and individuals without
psychosis (Table 2). In patients, early-onset users
showed higher mean total CC MD and total CC AD
than those who started using cannabis later, although
the difference was not statistically signiﬁcant. Also,
among individuals without psychosis, early-onset
users had a signiﬁcantly higher total CC MD and
total CC AD, than those who started later, although
this was not signiﬁcant. Comparisons of the CC
subsections are presented in the online
Supplementary material.
Discussion
To our knowledge, this is the ﬁrst study to investigate
the effect of cannabis potency and frequency on CC
WM microstructural organization, both in patients ex-
periencing their ﬁrst episode of psychosis and in can-
nabis users without psychosis. Our main ﬁnding,
which is in line with our main hypothesis, is that fre-
quent use of high-potency cannabis is signiﬁcantly
associated with altered callosal microstructural integ-
rity. Furthermore, our results suggest that this particu-
larly occurs in the most posterior part of the CC,
including the splenium and the posterior mid-body.
Interestingly, these alterations were similar in users
with and without a psychotic disorder.
Our ﬁndings support a role for frequent use of high-
potency cannabis in altered CC microstructure, sug-
gesting that callosal integrity may be particularly
sensitive to high THC concentration. CB1 receptors,
on which THC acts, have a known effect on oligo-
dendrocyte development (myelin initiation, depos-
ition, compaction and maintenance) (Davis et al.
2003). Hence, chronic or early exposure to high-THC
cannabis preparations, compared with those with low
THC, may alter WM through a down-regulation of
CB1 receptors. This may result in apoptosis of oligo-
dendrocyte progenitors during WM development
(Walter et al. 2003).
Although cannabis effects on WM have also been
related to use that occurs early, when WM is still devel-
oping and cannabis receptors are abundant, we found
no difference in WM integrity between individuals
who started younger or older than 15 years of age.
Still, considering that all our high-potency participants
started using in their teens, and that WM continues to
develop post-adolescence, it is possible that early
adulthood remains a period of vulnerability. Indeed,
one of the CC areas that we found to be most affected
by frequent high-potency cannabis use was the sple-
nium, which completes maturation only in young
adulthood, and later than other callosal parts, thus
remaining particularly susceptible to toxic effects of
cannabis (De Bellis et al. 2008). The splenium and the
posterior mid-body, which we also found particularly
affected, also contain motor ﬁbres (Zarei et al. 2006),
and their alteration may contribute to a dysfunction
of sensorimotor circuits, resulting in sensory percep-
tion alterations, impaired sensorimotor gating and hal-
lucinations, all of which have been associated with
cannabis abuse (Heng et al. 2011).
While one should be cautious about interpreting DTI
measures in terms of the pathological process that
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underlies microstructural changes, it is interesting that,
similarly to other studies, we found that cannabis po-
tency and frequency were associated with an increase
in MD, but with no changes in FA. MD is a non-
speciﬁc measure of integrity, and alterations in this
measure can result from changes in intra- or extra-
cellular space, including extra-cellular oedema, and
therefore be temporary and reversible (Bosch et al.
2012). Increases in MD are also observed in pathologies
accompanied by neuropil reduction and may reﬂect
demyelination or axonal loss (Selemon et al. 1999).
Cannabis frequency and potency were also associated
with an increase in AD and, at trend level, RD. It is
possible that neurobiological changes such as ﬁbre re-
organization, glial alteration and even axonal degener-
ation induce water to diffuse in unanticipated
directions and therefore increase measures such as
AD (Beaulieu et al. 2002). The concordance of changes
in tensor metrics, with increases in MD, AD and RD,
can also lead to proportional non-signiﬁcant changes
in FA, as the ones seen in our study and similar to
those observed in other neurological disorders such
as Alzheimer’s disease (Acosta-Cabronero et al. 2010).
We were somewhat surprised to see that differences
in callosal integrity in relation to cannabis potency
were larger in the individuals without psychosis than
in the patients. Comparison with other structural neu-
roimaging studies of cannabis use in FEP patients is
difﬁcult as only three studies to date have used DTI
and none has examined patterns of cannabis use.
Dekker et al. (2010) found reduced callosal FA in a
small sample of eight cannabis-naive patients with
schizophrenia compared with 10 early-user patients,
and no morphological differences between early-onset
and late-onset cannabis users with schizophrenia.
Unfortunately, the study did not report MD or AD
values. In contrast, James et al. (2011) found that
early cannabis use in adolescent-onset schizophrenia
was associated with lower FA in the brain stem, in-
ternal capsule, corona radiata, and superior and infer-
ior longitudinal fasciculi. Finally, a recent study in FEP
patients found no brain-wide differences in grey mat-
ter or WM between lifetime heavy and light users, or
non-users (Haller et al. 2013). Several methodological
differences may explain these inconsistencies. For ex-
ample, most studies used small samples, and subjects
varied in age range and diagnosis, with most including
only patients with schizophrenia rather than all psych-
oses. Also, the methods used to examine WM differ
across studies. These factors potentially affect all neu-
roimaging investigations and make it difﬁcult to ex-
trapolate whether differences in ﬁndings are due to
sample characteristics or methods used. Still, it is pos-
sible that the alterations in WM microstructure we
detected in our early, high-potency cannabis-user
patients would become even more signiﬁcant if a
larger sample is examined. Of note, we did not ﬁnd
differences in the proportion of cannabis users and
the related patterns of use across diagnostic groups.
This is an important clinical issue and a study with a
larger sample size would allow a more speciﬁc evalu-
ation of the role of diagnosis in relation to pattern of
cannabis use and brain structure in psychosis.
Our data go further than previous evidence and sug-
gest that cannabis potency and frequency affect the CC
in individuals with and without psychosis, and pos-
sibly reﬂect a subtle and general effect rather than
altered neuronal integrity. This is consistent with evi-
dence of callosal alterations in non-psychotic long-term
and heavy cannabis users (Arnone et al. 2008; Zalesky
et al. 2012). Overall, the ﬁnding is even more interest-
ing when we consider that on direct comparison, our
patients had signiﬁcantly lower callosal FA values
than individuals without psychosis, suggesting that:
(a) our patients have alterations similar to those previ-
ously reported in psychosis samples (Lener et al. 2015);
and (b) that this was apparent even though our indivi-
duals without psychosis included cannabis users.
This study has a number of strengths. We have eval-
uated the role of cannabis potency in relation to brain
structure for the ﬁrst time. Furthermore, we have used
a sample larger than those used in previous studies,
and evaluated users both with and without psychosis.
This has allowed us to provide data on the effects of
cannabis potency and pattern of use independently
of the presence of psychosis. In addition, all our
patients were at their ﬁrst psychotic episode.
Therefore, cannabis use had occurred prior to (or
around) illness onset, and not as a consequence
of the illness. Also, patients were not exposed to
long-term pharmacological treatment, making it un-
likely that WM alterations were due to antipsychotic
medications. Finally, we used a reliable and compre-
hensive ﬁbre-tracking method for the evaluation of
the CC, which has additionally provided details on
the integrity of its subsections.
Although our sample is one of the largest in which
WM and cannabis use have been evaluated, the num-
ber of subjects using low-potency cannabis was rela-
tively small. This may actually reﬂect the shift that
has occurred in the UK towards use of more high-
potency cannabis, which also reassures us that partici-
pants were more likely to admit to their use. The lack
of objective measures of cannabis use is another im-
portant limitation. However, other studies that have
used self-report measures have also shown an associ-
ation with brain structural alterations (Yücel et al.
2008; Cousijn et al. 2012). The fact that many of the
individuals without psychosis admitted to their canna-
bis use also gives us conﬁdence that participants were
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honest and open about their pattern of use.
Nevertheless, in a random sample of 56 cases from
the original sample, we carried out a urine drug screen
to test the reliability of data on current use (up to 4
weeks prior to the assessment). Of the 56 cases tested,
34 had reported they were not current users; 32 of
these (94%) had a negative urinary drug screening;
only two tested positive (Di Forti et al. 2012). In add-
ition, there is published evidence indicating that asking
patients with psychosis and individuals from the gen-
eral population about their use of cannabis is, at least
in some situations, more accurate than, or as reliable
as, urine or blood testing which can only provide infor-
mation on recent use (Hjorthøj et al. 2011; Freeman
et al. 2014). Finally, the accuracy of the neuroimaging
approach we used is contingent on its reliability, and
tensorial tractography models such as those used in
this study fail to map multiple ﬁbre orientations in
one voxel, and therefore may fail to map the ﬁbres of
the CC lateral to the crossing with the cortico-spinal
tract. Tractography nevertheless uses information
from a larger part of the tract than either voxel-based
or tract-based spatial statistics (TBSS) methods of ana-
lysis and may therefore be preferable (Dell’Acqua et al.
2013).
This study provides the ﬁrst report that WM dis-
array is greater among heavy users of high-potency
cannabis, than in occasional or low-potency users,
and that this is independent of the presence of a psych-
otic disorder. Unfortunately, high-potency cannabis is
replacing traditional herbal cannabis preparations in
many European countries. Raising awareness about
the risks of high-potency cannabis abuse seems there-
fore crucial. It will be extremely important that future
studies evaluating the effects of cannabis use on
brain structure and function include a careful assess-
ment of cannabis potency.
Supplementary material
For supplementary material accompanying this paper
visit http://dx.doi.org/10.1017/S0033291715002342
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